Join the Society for FREE Today!
SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.
SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.
Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.
The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The fourteenth annual meeting of the Society of Hematologic Oncology (SOHO 2026) is scheduled for September 9-12, 2026 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2026 offers in-person, virtual and on-demand participation.
The Ambassador program was created to increase geographical diversity
promote international understanding among hematologic oncology experts around the world.
promote international understanding among
hematologic oncology experts around the world.
If you are interested Contact Us!
Tafasitamab plus lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) improved progression-free survival (PFS) compared with R-CHOP alone and had manageable safety for patients with aggressive B-cell lymphomas in the phase 3 frontMIND study, according to a pre
The multicenter study incorporated a 3+3 dose de-escalation design followed by dose-expansion at the recommended phase 2 dose of ibrutinib 560 mg daily. The study included adults with stage 2-4 HIV-related DLBCL who were treatment-naïve or had previo
Oncologist migration patterns in the US may drive geographical care disparities, according to a poster presented at ASCO 2026.
The US Food and Drug Administration has granted Orphan Drug Designation to EO2463 immunotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL) in